ENGN

enGene Therapeutics Inc

1.53

Oct 29 • 3:59 PM ET -0.05 (-3.16%)

1.53

Aftermarket • 4:15 PM ET 0.00 (0.00%)

Healthcare Biotechnology Canada Micro NASD

Peers: CGON TARA IBRX URGN AURA GNLX INO REPL JNJ CTMX

Scroll to Statements

Index	-
Market Cap	102.54M
Enterprise Value	-130.59M
Income	-130.36M
Sales	0.00M
Book/sh	3.44
Cash/sh	3.97
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	82
IPO	Feb 01, 2022

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.45
P/C	0.38
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	10.21
Current Ratio	10.21
Debt/Eq	0.14
LT Debt/Eq	0.13
Option/Short	Yes / Yes

EPS (ttm)	-2.08
EPS next Y	-1.50
EPS next Q	-0.46
EPS this Y	20.83%
EPS next Y	17.38%
EPS next 5Y	23.88%
EPS past 3/5Y	- -255.92%
Sales past 3/5Y	- -
EPS Y/Y TTM	-9.75%
Sales Y/Y TTM	-
EPS Q/Q	17.85%
Sales Q/Q	-
Earnings	Sep 08 BMO
EPS/Sales Surpr.	-10.17% -

Insider Own	57.56%
Insider Trans	0.01%
Inst Own	42.88%
Inst Trans	-21.10%
ROA	-48.84%
ROE	-60.50%
ROIC	-49.92%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-8.37%
SMA50	-15.16%
SMA200	-65.28%
Trades

Shs Outstand	67.01M
Shs Float	28.44M
Short Float	5.28%
Short Ratio	2.02
Short Interest	1.50M
52W High	12.25 -87.51%
52W Low	1.40 9.29%
Volatility	4.20% 5.39%
ATR (14)	0.09
RSI (14)	37.04
Beta	-0.29
Rel Volume	0.93
Avg Volume	742.10K
Volume	690,369

Perf Week	-3.16%
Perf Month	-23.50%
Perf Quarter	-14.53%
Perf Half Y	-78.95%
Perf YTD	-83.06%
Perf Year	-79.13%
Perf 3Y	-94.62%
Perf 5Y	-
Perf 10Y	-
Recom	2.30
Target Price	3.50
Prev Close	1.58
Price	1.53
Change %	-3.16%

Consensus

Buy

Avg. Price Target

$3.50

Implied Upside

+128.8%

Analysts13incl. previous ratings

Rating Distribution5 Buy · 7 Hold · 1 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Jun 18, 2026	Downgrade	MMorgan Stanley	Equal-Weight → Underweight
May 08, 2026	Downgrade	WWells Fargo	Overweight → Equal Weight	$2	+30.7%
May 08, 2026	Downgrade	RRaymond James	Strong Buy → Outperform	$4	+161.4%
May 08, 2026	Downgrade	PPiper Sandler	Overweight → Neutral	$4	+161.4%
May 08, 2026	Downgrade	OOppenheimer	Outperform → Perform
May 08, 2026	Downgrade	MMorgan Stanley	Overweight → Equal-Weight
May 08, 2026	Downgrade	LLeerink Partners	Outperform → Market Perform	$2	+30.7%
May 08, 2026	Downgrade	GGuggenheim	Buy → Neutral
May 08, 2026	Downgrade	CCitizens	Mkt Outperform → Mkt Perform
Apr 13, 2026	Initiated	WWBB Securities	Buy	$21.50	+1,305.2%
Jan 30, 2026	Initiated	JJefferies	Buy	$28	+1,730.1%
Nov 11, 2025	Upgrade	RRaymond James	Outperform → Strong Buy	$27	+1,664.7%
Feb 18, 2025	Initiated	PPiper Sandler	Overweight	$26	+1,599.3%
Feb 14, 2025	Downgrade	UUBS	Buy → Neutral	$34 → $7	+357.5%
Dec 23, 2024	Initiated	HH.C. Wainwright	Buy	$25	+1,534.0%
Nov 27, 2024	Initiated	RRaymond James	Outperform	$23	+1,403.3%
Nov 18, 2024	Initiated	JJMP Securities	Mkt Outperform	$18	+1,076.5%
Aug 28, 2024	Initiated	OOppenheimer	Outperform	$30	+1,860.8%
Apr 22, 2024	Initiated	WWells Fargo	Overweight	$30	+1,860.8%
Apr 15, 2024	Initiated	GGuggenheim	Buy	$34	+2,122.2%

Sep-01-26 08:30AM	enGene to Participate in Upcoming Investor Conferences (Business Wire)
Aug-04-26 08:00AM	enGene to Host Virtual KOL Event to Discuss Emerging Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insights, on August 11, 2026 (Business Wire)
Jul-16-26 08:00AM	enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones (Business Wire)
Jun-16-26 05:08AM	Neumora depression drug fails; EnGene to cut 50% of staff (BioPharma Dive)
Jun-15-26 09:00AM	enGene Reports Second Quarter 2026 Financial Results and Provides Business Update (Business Wire) +9.26%
11:41AM	Loading…
May-08-26 11:41AM	enGene Therapeutics hit by analyst downgrades as drug data disappoints (Investing.com) -12.79%
May-07-26 07:00AM	enGene Announces Updated Interim Results From LEGEND Pivotal Cohort (Business Wire) -80.56%
Apr-07-26 08:00AM	enGene Announces Name Change to enGene Therapeutics Inc. (Business Wire)
Mar-09-26 07:00AM	enGene Reports First Quarter 2026 Financial Results and Provides Business Update (Business Wire) -18.78%
Feb-27-26 07:16PM	enGene Maps BLA by End-2026, Targets 2027 Launch for Lead NMIBC Therapy at Oppenheimer Conference (MarketBeat)
Feb-20-26 08:00AM	enGene to Participate in Upcoming Investor Conferences (Business Wire)
Feb-16-26 07:04AM	Jefferies Sets a $28 PT for enGene Holdings Inc. (ENGN) (Insider Monkey)
Feb-12-26 05:02AM	enGene CEO Talks Detalimogene for Community Urology as LEGEND Study Hits Full Enrollment (MarketBeat)
Feb-04-26 08:00AM	enGene to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 (Business Wire)
Jan-30-26 09:54AM	Spotify upgraded, Pinterest downgraded: Wall Street's top analyst calls (The Fly) -7.21%
05:35PM	Loading…
Jan-20-26 05:35PM	enGene Announces Expanded $125 Million Debt Facility with Hercules Capital, Inc. (Business Wire)
Dec-22-25 04:03PM	enGene Reports Full Year 2025 Financial Results and Provides Business Update (Business Wire) +5.13%
Dec-04-25 10:09PM	enGene Holdings Inc (ENGN) Surging After Positive Phase 2 LEGEND Trial (Insider Monkey)
Dec-02-25 07:30AM	enGenes Detalimogene Selected for FDA Manufacturing Pilot Program to Support Manufacturing Readiness (Business Wire)
Nov-25-25 07:30AM	enGene to Present at the Piper Sandler 37th Annual Healthcare Conference (Business Wire)
Nov-13-25 12:27AM	enGene Announces Pricing of $130 Million Public Offering of Common Shares and Pre-Funded Warrants (Business Wire)
Nov-12-25 04:01PM	enGene Announces Proposed Public Offering of Common Shares (Business Wire)
Nov-11-25 12:04PM	enGenes NMIBC gene therapy touts 63% complete response in pivotal trial (Clinical Trials Arena) +46.76%
07:30AM	Detalimogene Demonstrates Improved Complete Response Rate of 62% at 6 Months (Business Wire)
Nov-10-25 04:05PM	enGene to Host Conference Call to Provide Update on Pivotal Cohort of LEGEND Trial (Business Wire)
Nov-06-25 05:00PM	enGene to Participate in Upcoming Investor Conferences (Business Wire) -5.05%
Nov-04-25 01:35PM	enGene Named a BioSpace 2026 Best Places to Work Winner (Business Wire) -5.64%
Oct-07-25 08:00AM	Novel Cancer Platforms Converge as Clinical Data Reshapes Treatment Paradigms (PR Newswire) -7.76%
Oct-01-25 04:03PM	enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire) +11.27% +7.11%
Sep-11-25 04:03PM	enGene Reports Third Quarter 2025 Financial Results and Provides Business Update (Business Wire) -5.78%
07:30AM	Loading…
Sep-03-25 07:30AM	enGene Achieves Target Enrollment Milestone for LEGEND Trial Pivotal Cohort (Business Wire)
Aug-27-25 08:00AM	enGene to Participate in Upcoming Investor Conferences (Business Wire)
Aug-04-25 08:00AM	enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Jul-08-25 08:00AM	enGene Announces Board and Leadership Appointments to Support Commercial Readiness (Business Wire)
Jun-25-25 08:00AM	FDA Grants RMAT Designation for enGenes Detalimogene, Enabling Potential for Expedited Review in High-Risk, Non-Muscle Invasive Bladder Cancer (Business Wire) +9.03%
Jun-17-25 08:00AM	enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Jun-12-25 08:00AM	enGene Reports Second Quarter 2025 Financial Results and Provides Business Update (Business Wire)
Jun-04-25 08:30AM	enGene Announces the Resignation of its Chief Medical Officer (Business Wire) -8.81%
May-29-25 08:00AM	enGene to Present at the Jefferies Global Healthcare Conference (Business Wire)
May-28-25 07:30AM	enGene Names Amy Pott as Chief Global Commercialization Officer (Business Wire)
Apr-29-25 07:30AM	enGene to Participate in Upcoming Investor Conferences (Business Wire)
Apr-28-25 08:00AM	enGene to Participate in Upcoming Investor Conferences (Business Wire)
Apr-23-25 10:13AM	Is enGene Holdings Inc. (ENGN) the Best Canadian Penny Stock to Invest in Now? (Insider Monkey)
Apr-04-25 08:00AM	enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Apr-01-25 08:00AM	enGene to Present at the Stifel 2025 Virtual Targeted Oncology Forum (Business Wire)
Mar-10-25 04:05PM	enGene Reports First Quarter 2025 Financial Results and Provides Business Update (Business Wire)
Mar-04-25 08:00AM	enGene to Participate in the Leerink Partners Global Healthcare Conference (Business Wire)
Feb-04-25 08:00AM	enGene to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference (Business Wire)
Jan-31-25 04:05PM	enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire) -5.63%
Jan-30-25 08:00AM	enGene to Present Three Posters at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) Highlighting the Ongoing Clinical Development of Detalimogene Voraplasmid for the Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC) (Business Wire)
Dec-30-24 04:05PM	enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire) +5.14%
Dec-19-24 04:05PM	enGene Reports Full Year 2024 Financial Results and Provides a Business Update (Business Wire)
Nov-25-24 08:00AM	enGene to Participate in Upcoming Investor Conferences (Business Wire) +7.94%
Nov-05-24 08:00AM	enGene to Participate in Guggenheims Inaugural Healthcare Innovation Conference (Business Wire)
Oct-25-24 08:00AM	enGene Announces $60 Million Private Placement Financing (Business Wire)
Oct-22-24 04:05PM	enGene Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Business Wire) -7.93%
Oct-21-24 08:45AM	enGene Appoints Joan Connolly as Chief Technology Officer and Anthony Cheung, Ph.D., as Chief Scientific Officer (Business Wire) +8.98%
Oct-01-24 04:05PM	enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Sep-26-24 06:30AM	Detalimogene Demonstrates 71% Complete Response Rate at Any Time in Preliminary Analysis of LEGEND Pivotal Cohort (Business Wire) -12.00%
Sep-14-24 10:08PM	enGene Holdings Inc. (ENGN): Wall Street Analysts Recommend This Canadian Stocks Right Now (Insider Monkey)
Sep-10-24 04:33PM	enGene Reports Third Quarter 2024 Financial Results and Provides a Business Update (Business Wire)
Aug-28-24 04:05PM	enGene to Participate in Upcoming Investor Conferences (Business Wire)
Jul-24-24 04:05PM	enGene Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
06:30AM	enGene Announces Appointment of Ron Cooper as Chief Executive Officer (Business Wire)
Jul-18-24 08:00AM	NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors (GlobeNewswire)
Jun-14-24 07:01AM	enGene Reports Second Quarter 2024 Financial Results and Provides a Business Update (Business Wire) -10.00%
May-29-24 07:30AM	enGene to Present at the Jefferies Global Healthcare Conference (Business Wire)
May-15-24 04:05PM	enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors (Business Wire)
May-02-24 04:05PM	enGene to Present Details of its Pivotal Phase 1/2 LEGEND Study of EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ at the American Urology Association 2024 Annual Meeting (PR Newswire)
Apr-09-24 08:56AM	/C O R R E C T I O N -- enGene Inc./ (PR Newswire)
08:00AM	engender Announces Hiring of Dr. Raja Ruth as Senior Vice President, Urologic Oncology and Clinical Development (PR Newswire)
Mar-11-24 05:16PM	enGene Reports First Quarter 2024 Financial Results and Recent Corporate Progress (PR Newswire)
Mar-05-24 07:00AM	enGene To Present at the Leerink Partners Global Biopharma Conference (PR Newswire)
Feb-14-24 06:50AM	enGene Announces Oversubscribed $200 Million Private Placement Financing (PR Newswire) +116.54%
06:45AM	enGene Announces Leadership Succession Plan (PR Newswire)
Jan-30-24 07:00AM	enGene Appoints Lee Giguere as Chief Legal Officer and Corporate Secretary (PR Newswire) -7.11%
Jan-29-24 07:00AM	enGene Reports Full Year 2023 Financial Results and Recent Operational Progress (PR Newswire)
Dec-22-23 05:00PM	enGene Announces Expanded $50 Million Debt Facility with Hercules Capital (PR Newswire)
Dec-19-23 07:00AM	enGene Appoints Lota S. Zoth, CPA, as Member of the Board of Directors (PR Newswire) +6.10%
Nov-29-23 07:00AM	enGene Appoints Ryan Daws as Chief Financial Officer (PR Newswire) -11.14%
Nov-13-23 09:55AM	Forbion co-leads 129 million Series A financing of VectorY, one of the largest private biotech financings in Europe in 2023 (GlobeNewswire) +5.36%
Nov-02-23 07:00AM	Lumira Ventures Portfolio Company enGene (Nasdaq:ENGN) Debuts as Publicly Traded Genetic Medicines Company (ACCESSWIRE) -5.00%
Nov-01-23 07:30AM	enGene (Nasdaq: ENGN) Launched as Publicly Traded Genetic Medicines Company (PR Newswire) -7.81%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Grossman William	Interim Chief Medical Officer	Sep 22 '26	Buy	1.97	5,102	10,051	5,102	Sep 24 04:40 PM

enGene Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in developing gene therapies. It is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs. The company was founded by Anthony T. Cheung on April 24, 2023 and is headquartered in Saint-Laurent, Canada.

PresidentMr. Ronald H. W. Cooper

Ph.D.Dr. William J. Grossman M.D.

Senior VP of FinanceMs. Kathleen Richton

Chief Technology OfficerMs. Joan Connolly

Senior VP of Human ResourcesMs. Tara Place M.B.A.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ENGN

enGene Therapeutics Inc

Upgrade your Finviz experience